Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Operating Expenses (2017 - 2019)

Historic Operating Expenses for Monopar Therapeutics (MNPR) over the last 3 years, with Q4 2019 value amounting to $1.2 million.

  • Monopar Therapeutics' Operating Expenses rose 3222.7% to $1.2 million in Q4 2019 from the same period last year, while for Sep 2020 it was $1.2 million, marking a year-over-year decrease of 6956.95%. This contributed to the annual value of $4.3 million for FY2019, which is 2979.8% up from last year.
  • Per Monopar Therapeutics' latest filing, its Operating Expenses stood at $1.2 million for Q4 2019, which was up 3222.7% from $759448.0 recorded in Q3 2019.
  • Monopar Therapeutics' 5-year Operating Expenses high stood at $14.9 million for Q3 2017, and its period low was $373839.0 during Q1 2017.
  • Over the past 3 years, Monopar Therapeutics' median Operating Expenses value was $828354.0 (recorded in 2018), while the average stood at $2.0 million.
  • The largest annual percentage gain for Monopar Therapeutics' Operating Expenses in the last 5 years was 14001.24% (2018), contrasted with its biggest fall of 9551.92% (2018).
  • Monopar Therapeutics' Operating Expenses (Quarter) stood at $736800.0 in 2017, then increased by 25.73% to $926358.0 in 2018, then skyrocketed by 32.23% to $1.2 million in 2019.
  • Its last three reported values are $1.2 million in Q4 2019, $759448.0 for Q3 2019, and $932109.0 during Q2 2019.